Altered expression of genes profiles modulated by a combination of Astragali Radix and Angelicae Sinensis Radix in obstructed rat kidney

Planta Medica

Volumn 76, Issue 13, 2010, Pages 1431-1438

  Meng, Liqiang ^a,b   Van Putten, Vicki ^c   Qu, Lei ^a,b   Nemenoff, Raphael A ^c   Shang, Ming Ying ^a   Cai, Shao Qing ^a   Li, Xiaomei ^a,b  

^a PEKING UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Angelica sinensis; Astragalus membranaceus var. mongholicus; Leguminosae; microarray; renal fibrosis; Umbelliferae; unilateral ureteral obstruction

Indexed keywords

ANGELICA SINENSIS EXTRACT; ASTRAGALI RADIX EXTRACT; BONE MARROW STROMAL CELL ANTIGEN 1; CELL PROTEIN; CELL RECEPTOR; CYTOCHROME P450 1A1; FIBROBLAST GROWTH FACTOR 23; PEROXISOMAL BIOGENESIS FACTOR 6; PLANT EXTRACT; SERINE PROTEINASE INHIBITOR; TRANSIENT RECEPTOR PROTEIN 3; UNCLASSIFIED DRUG; XANTHINE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTRAGALI RADIX; CONTROLLED STUDY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; KIDNEY; MALE; MEDICINAL PLANT; NONHUMAN; NUCLEOTIDE SEQUENCE; OBSTRUCTIVE UROPATHY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WISTAR RAT;

ANGELICA SINENSIS; ANIMALS; ASTRAGALUS PLANT; CALCIUM; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; KIDNEY; KIDNEY DISEASES; MALE; PHOSPHATES; PHYTOTHERAPY; PLANT ROOTS; RANDOM ALLOCATION; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RENAL AGENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; URETERAL OBSTRUCTION;

ANGELICA SINENSIS; ANIMALIA; APIACEAE; ASTRAGALUS MEMBRANACEUS VAR. MONGHOLICUS; FABACEAE; RATTUS; RATTUS NORVEGICUS;

EID: 77956674600     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0029-1240943     Document Type: Article

References (28)

1. Li L, Yu H, Pan J. A study on protein metabolism in nephrotic patients treated with Chinese herbs (Chinese). Zhonghua Nei Ke Za Zhi 1995 34 670-672
2. Wang H, Li J, Yu L, Zhao Y, Ding W. Antifibrotic effect of the Chinese herbs, Astragalus mongholicus and Angelica sinensis, in a rat model of chronic puromycin aminonucleoside nephrosis. Life Sci 2004 74 1645-1658
3. Zhao J R., Qu L, Li X M. Preventive and therapeutic effects of Astragalus and Angelica mixture on renal tubulointerstitial fibrosis after unilateral ureteral obstruction in rats (Chinese). Beijing Da Xue Xue Bao 2004 36 119-123
4. Meng L, Qu L, Tang J, Cai S Q., Wang H, Li X. A combination of Chinese herbs, Astragalus membranaceus var. mongholicus and Angelica sinensis, enhanced nitric oxide production in obstructed rat kidney. Vasc Pharmacol 2007 47 174-183
5. Huang H C., Min Y L., Li J Z., Wang H Y. Comparative effects between Astragalus-Angelica mixture and enalapril on expression of connective tissue growth factor in rats with renal tubulointerstitial fibrosis (Chinese). Chin J Nephrol 2003 19 133-136
6. Wang R, Li X M., Li J Z., Wang H Y. The effect of astragali and angelica on renal cell transdifferentiation and MAPK pathway in chronic puromycin aminonucleoside nephrosis (PAN) (Chinese). Chin Pharm Bull 2003 19 1069-1074
7. Xiao H B., Liang X M., Lu P Z., Chen Z J. New analysis methodology and application for Chinese prescription (Chinese). Chin Sci Bull 1999 44 588-596
8. Xu L W., Shang M Y., Li J, Li X M., Meng L Q., Cai S Q. Analysis of principal composition of ethyl acetate part in Huangqi Danggui decoction by HPLC-ESI-TOF-MS (Chinese). Zhongguo Zhong Yao Za Zhi 2008 33 2508-2512
9. Hsiao L L., Stears R L., Hong R L., Gullans S R. Prospective use of DNA microarrays for evaluating renal function and disease. Curr Opin Nephrol Hypertens 2000 9 253-258
10. Bascands J L., Schanstra J P. Obstructive nephropathy: insights from genetically engineered animals. Kidney Int 2005 68 925-937
11. Eddy A A., Fogo A B. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006 17 2999-3012
12. Oikawa T, Freeman M, Lo W, Vaughan D E., Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 1997 51 164-172
13. Ma L J., Nakamura S, Aldigier J C., Rossini M, Yang H, Liang X, Nakamura I, Marcantoni C, Fogo A B. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005 16 966-976
14. Oda T, Jung Y O., Kim H S., Cai X, López-Guisa J M., Ikeda Y, Eddy A A. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 2001 60 587-596
15. Ossowski L, Aguirre-Ghiso J A. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000 12 613-620
16. Kjøller L. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol Chem 2002 383 5-19
17. Czekay R P., Aertgeerts K, Curriden S A., Loskutoff D J. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003 160 781-791
18. Cave A C., Brewer A C., Narayanapanicker A, Ray R, Grieve D J., Walker S, Shah A M. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 2006 8 691-728
19. McNally J S., Saxena A, Cai H, Dikalov S, Harrison D G. Regulation of xanthine oxidoreductase protein expression by hydrogen peroxide and calcium. Arterioscler Thromb Vasc Biol 2005 25 1623-1628
20. Ricardo S D., Ding G, Eufemio M, Diamond J R. Antioxidant expression in experimental hydronephrosis: role of mechanical stretch and growth factors. Am J Physiol 1997 272 F789-F798
21. Chiu P Y., Leung H Y., Siu A H., Poon M K., Dong T T., Tsim K W., Ko K M. Dang-Gui Buxue Tang protects against oxidant injury by enhancing cellular glutathione in H9c2 cells: role of glutathione synthesis and regeneration. Planta Med 2007 73 134-141
22. Liu S, Quarles L D. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007 18 1637-1647
23. Fukagawa M, Nii-Kono T, Kazama J J. Role of fibroblast growth factor 23 in health and in chronic kidney disease. Curr Opin Nephrol Hypertens 2005 14 325-329
24. Mirams M, Robinson B G., Mason R S., Nelson A E. Bone as a source of FGF23: regulation by phosphate? Bone 2004 35 1192-1199
25. Fukagawa M, Kazama J J. FGF23: its role in renal bone disease. Pediatr Nephrol 2006 21 1802-1806
26. Tian J, Liu Y, Williams L A., Zeeuw D D. Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrol Dial Transplant 2007 22 321-328
27. Ma Q, Lu A Y. CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab Dispos 2007 35 1009-1016
28. Rong J, Tilton R, Shen J, Ng K M., Liu C, Tam P K., Lau A S., Cheng Y C. Genome-wide biological response fingerprinting (BioReF) of the Chinese botanical formulation ISF-1 enables the selection of multiple marker genes as a potential metric for quality control. J Ethnopharmacol 2007 113 35-44